Sanofi acquires Massachusetts biotech Blueprint for $9.1 billion
New England Council member Sanofi, originally a French pharmaceutical and healthcare company, is now a multinational corporation with a significant presence in New England. It recently acquired the Massachusetts-based company, Blueprint Medicines.
This news follows a large sale by Sanofi in late April. Sanofi sold its controlling stake in the consumer health business, Opella, for $11.4 billion. About a month and a half ago, in early June, Sanofi announced the purchase of Blueprint Medicines for $9.1 billion. This acquisition marks a shift for Sanofi, as it continues to move away from its initial focus on cancer therapies and shift toward immunology. This is the company’s biggest acquisition since 2018 with Bioverativ Inc., an offshoot of Biogen Inc.
This “complements recent acquisitions of early-stage medicines that remain our main field of interest. Sanofi still retains a sizeable capacity for further acquisitions,” said Sanofi’s CEO, Paul Hudson.
The New England Council commends Sanofi for its ongoing commitment to advancing immunology science in the region.
Read more via The Boston Globe